MedTrace Logo

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01043666 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1126

Last updated 2024-10-31

No results posted yet for this study

Summary

This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

YM178

oral

DRUG

Placebo

oral

DRUG

tolterodine ER

oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-21
Primary Completion
2011-09-16
Completion
2011-09-16

Countries

  • China
  • India
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01043666 on ClinicalTrials.gov